Novartis scores FDA nod for game-changing SMA treatment
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The State’s PPP model has already mobilised Rs. 150 crore in core infrastructure, while Thermo Fisher has invested Rs. 90 crore in the Bioprocess Design Centre and its co-located Customer Experience Centre
A key highlight will be Brenntag’s qualified amino acids portfolio
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
Jaypirca is making waves in the fight against B-cell malignancies
The deal accelerates GE HealthCare’s digital transformation, expanding its reach into outpatient care and enterprise imaging—a $2 billion-plus growth market
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
Winlevi is authorized in EU for the treatment of acne vulgaris
Subscribe To Our Newsletter & Stay Updated